Foghorn Therapeutics (FHTX) Net Margin (2020 - 2025)
Historic Net Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 202.0%.
- Foghorn Therapeutics' Net Margin rose 429000.0% to 202.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 305.82%, marking a year-over-year increase of 517100.0%. This contributed to the annual value of 383.24% for FY2024, which is 950700.0% down from last year.
- Latest data reveals that Foghorn Therapeutics reported Net Margin of 202.0% as of Q3 2025, which was up 429000.0% from 248.62% recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Net Margin registered a high of 82.07% during Q3 2023, and its lowest value of 65268.29% during Q3 2021.
- For the 5-year period, Foghorn Therapeutics' Net Margin averaged around 4871.6%, with its median value being 526.65% (2023).
- Per our database at Business Quant, Foghorn Therapeutics' Net Margin plummeted by -548263900bps in 2021 and then soared by 648798500bps in 2022.
- Over the past 5 years, Foghorn Therapeutics' Net Margin (Quarter) stood at 3998.32% in 2021, then surged by 83bps to 690.39% in 2022, then surged by 39bps to 417.85% in 2023, then plummeted by -63bps to 682.88% in 2024, then soared by 70bps to 202.0% in 2025.
- Its Net Margin stands at 202.0% for Q3 2025, versus 248.62% for Q2 2025 and 339.73% for Q1 2025.